Drugs / Ubamatamab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07637851 | Aug 2026 → Sep 2028 expected | ovarian cancer | ARCAGY/ GINECO GROUP | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04590326 | Dec 2020 → Mar 2027 expected | endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03564340 | May 2018 → May 2027 expected | endometrial cancer, fallopian tube cancer, malignant ovarian serous tumor, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07154290 | Mar 2026 → Jun 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06787612 | May 2025 → Oct 2028 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06444880 | Oct 2024 → Jul 2028 expected | epithelioid sarcoma, kidney medullary carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07502716 Background | — | epithelioid sarcoma, kidney medullary carcinoma | Regeneron Pharmaceuticals | Available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ubamatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07637851 ↗ |
| Known as | REGN-4018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594595 ↗ |
| Action | Deplete | “promotes T-cell-mediated cytotoxicity of MUC16-expressing cells” PMID 39652449 ↗ Dec 2024 |
| Modality | Monoclonal antibody | — CHEMBL4594595 ↗ |
| Route | Intravenous | “Intravenous administration of ubamatamab” PMID 39652449 ↗ Dec 2024 |
| Target | MUC16 | “a novel bispecific T-cell engager (MUC16xCD3)” PMID 40749151 ↗ Aug 2025 |